Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer (Q63807803)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer |
clinical trial |
Statements
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy (English)
0 references
15 November 2016
0 references
31 May 2026
0 references
1,000
0 references
18 year
0 references